The liver plays a vital role in several key bodily functions, including metabolism, detoxification, and digestion. Due to its rich blood supply and complex structure, it is also susceptible to abnormal growths, some of which may be benign while others can be malignant. Also read | Doctors warn: Liver cancer could hit you in your … Read more
Researchers discover that inflammation and aging contribute to non-viral liver cancer development. Green tea’s role in reversing some of the pathway dysregulation that may contribute to the cancer development and other therapies explored. Liver cancer can arise spontaneously from healthy liver tissue. Recently, however, researchers have discovered an increasing correlation between some liver cancers and … Read more
Photo: Stepan Popov/Adobe Stock With chronic hepatitis potentially being more common in cats than believed, according to a feline virologist at the City University of Hong Kong, a group of researchers and specialists are coming together to study the first hepatitis B-related virus found in carnivores. Specifically, their research will center on how the virus … Read more
According to a press release, Antengene Corporation, the developer of camrelizumab, will contact the FDA to address concerns raised in the CRL. The FDA granted a second complete response letter (CRL) to camrelizumab in combination with rivoceranib as a first line of treatment for patients with unresectable or metastatic hepatocellular carcinoma (HCC), according to a … Read more
Hepatitis C virus (HCV) infection remains a major global health burden, affecting millions worldwide and contributing significantly to hepatocellular carcinoma (HCC) development. The introduction of direct-acting antivirals (DAAs) has revolutionized HCV treatment, achieving high rates of sustained virologic response (SVR) and reducing HCV-associated morbidity and mortality. Despite these advancements, the risk of HCC persists in … Read more
Updated data from key trials with immune checkpoint inhibitor (ICI) regimens, including those from the 4-year overall survival (OS) analysis of the phase 3 HIMALAYA trial (NCT03298451), continue to show why ICI-based combinations are the frontline treatment of choice for patients with hepatocellular carcinoma (HCC), according to Gentry King, MD. “[HIMALAYA was] another study that … Read more
A new study reveals that even low-dose, chronic exposure to air pollution can trigger liver inflammation, fibrosis, and metabolic disruptions, increasing the risk of fatty liver disease and other hepatic disorders. Study: Mouse study demonstrates liver damage from low-level PM2.5 exposure. Image Credit: Shutterstock AI Generator / Shuttersotck.com A recent study published in the Journal of … Read more
A large-scale study reveals azvudine’s comparable efficacy to Paxlovid, fewer adverse effects, and potential antitumor benefits in patients with liver cancer. Study: Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study. Image Credit: Cryptographer/Shutterstock.com In a recent study published in the Signal Transduction and Targeted Therapy, a … Read more
Background and aims The quantitative effects of alcohol consumption on cirrhosis and hepatocellular carcinoma (HCC) in hepatitis B virus (HBV) infection are unknown. This study aimed to establish a dose-dependent model of alcohol consumption on the risks of cirrhosis and HCC. Methods PubMed, Embase, the Cochrane Library, Web of Science, and four Chinese databases were … Read more
Schlaak JF. Current Therapy of Chronic Viral Hepatitis B, C and D. J Pers Med. 2023;13:964. Article PubMed PubMed Central Google Scholar Burén S, Gomes AL, Teijeiro A, Fawal M-A, Yilmaz M, Tummala KS, et al. Regulation of OGT by URI in Response to Glucose Confers c-MYC-Dependent Survival Mechanisms. Cancer Cell. 2016;30:290–307. Article CAS PubMed … Read more